Clinical trials: Urinary System Tumor
Wilms Tumor, Renal Cancer
Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared
Indocyanine Green (ICG) is a dye which fluoresces under near-infrared (NIR) light. It has been used for several applications in adult surgery.
- Trial name
- Nephrogreen (NCT05735977)
- Testing
- Indocyanine Green (ICG)
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
A single-arm, prospective, exploratory clinical trial to explore the pathological complete response (pCR) rate of immune checkpoint inhibitors combined with antibody conjugate drugs as the perioperative treatment of…
- Trial name
- NCT06341400
- Testing
- DisitamabVedotinForIicction Toripalimab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Zhujiang Hospital
Kidney Cancer
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00042965
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 50 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Renal Cell Carcinoma
Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT06032728
- Testing
- Sunitinib
- Volunteers
- 488 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer
Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer
Main objectives: Qualitative and quantitative monitoring of recurrences in patients with a previous diagnosis of high-grade bladder cancer at high risk of persistence/recurrence.
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer, Bladder Tumors, Bladder Cancer Recurrence
- Trial name
- LIBERO (NCT06751667)
- Testing
- Urinary biomarkers
- Volunteers
- 50 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Nephroblastoma (Wilms Tumour)
DWI in the Diagnosis of Histological Types of Nephroblastoma in Children
Initially, or after preoperative chemotherapy, patients with a kidney tumor are examined on 3T MR scanner or 1.5T MR scanner. A standard MRI study of the abdomen with contrast enhancement is performed.
- Trial name
- NCT04814758
- Testing
- MRI DWI sequence (ADC values)
- Where
- Russia
- Volunteers
- 230 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Bladder Carcinoma
EffectiveNess of a Multimodal preHAbilitation Program in patieNts With Bladder canCEr Undergoing Cystectomy
Currently, the potential value of a multimodal prehabilitation program in bladder cancer has not been extensively studied. The investigators designed the ENHANCE study to assess the effect of a structured multimodal…
- Trial name
- ENHANCE (NCT05480735)
- Testing
- Prehabilitation
- Where
- 8 sites in Netherlands
- Volunteers
- 154 people
- Sponsor
- The Netherlands Cancer Institute
Uterine Cancer, Rectal Cancer
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Female patients with early onset (<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk…
- Conditions
- Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer
- Trial name
- OvAR-Y (NCT06904365)
- Testing
- HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Bladder Cancer
Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as carbogen and niacinamide may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00033436
- Testing
- niacinamide, carbogen, radiation therapy
- Where
- 14 sites in United Kingdom
- Volunteers
- 330 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with…
- Trial name
- SunRISe-1 (NCT04640623)
- Testing
- TAR-200, Cetrelimab
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer
TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
The purpose of this study is to describe the safety and tolerability of Durvalumab plus Tremelimumab followed by concurrent Durvalumab plus bladder radiation in patients with localized muscle invasive urothelial carcinoma of the…
- Trial name
- TRIO Bladder (NCT04073160)
- Testing
- Tremelimumab, Durvalumab, Bladder radiation
- Where
- United States
- Sponsor
- Daniel George, MD
Carcinoma, Renal Cell, Melanoma
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with…
- Trial name
- NCT00356460
- Testing
- GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody, GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Genzyme, a Sanofi Company
Kidney Cancer
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- SURTIME (NCT01099423)
- Testing
- timing of surgery, gene expression analysis, biologic sample preservation procedure
- Where
- 29 sites in Belgium, Canada and 3 more
- Volunteers
- 99 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Superficial Bladder Cancer
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
The purpose of this study is to determine whether neoadjuvant intravesical Gemcitabine is enough active in patients with a solitary, low risk superficial bladder cancer.After diagnostic urethrocystoscopy or bladder sonography…
- Trial name
- NCT00191711
- Testing
- Gemcitabine
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
This phase II trial tests adding VSV-IFNβ-NIS to standard of care ipilimumab and nivolumab for the treatment of clear cell renal cell carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07510334
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Lung Cancer, Breast Cancer
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps.
- Conditions
- Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer
- Trial name
- SkinHealth (NCT05878964)
- Testing
- EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bladder Cancer, Invasive Bladder Cancer
Nordic Cystectomy Study III - Transfusion
Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked with high mortality rates.
- Trial name
- NorCys-Transf (NCT04537221)
- Testing
- Blood transfusion
- Where
- Finland
- Volunteers
- 1,700 people
- Sponsor
- Turku University Hospital
Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer.
- Trial name
- NCT01915121
- Testing
- Education Intervention, Nutrition Intervention
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cardiovascular Disorder, Chronic Kidney Disease
Cancer and Blood Pressure Management, CARISMA Study
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are…
- Conditions
- Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma
- Trial name
- NCT04467021
- Testing
- Best Practice, Blood Pressure Measurement, Clinical Management
- Where
- 25 sites in United States
- Volunteers
- 61 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.